B-type natriuretic peptide in ischemic heart disease

被引：17

作者：

Rajat Deo

James A. de Lemos

机构：

[1] Division of Cardiology, University of Texas, Southwestern Medical Center, Dallas, TX 75390-9047

来源：

Current Cardiology Reports | 2003年 / 5卷 / 4期

关键词：

Natriuretic Peptide; Brain Natriuretic Peptide; Nesiritide; Plasma Brain Natriuretic Peptide; Orbofiban;

D O I：

10.1007/s11886-003-0062-8

中图分类号：

学科分类号：

摘要：

B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (N-proBNP) are released from the heart in response to increased wall stress. Assays for these peptides are now commercially available, and measurement of BNP and N-proBNP is becoming commonplace in patients with suspected heart failure. BNP and N-proBNP facilitate diagnosis and risk stratification in patients with heart failure, and may help guide response to therapy. This review focuses on the emerging role of BNP and N-proBNP measurement in patients with acute coronary syndromes (ACS). Although experimental studies demonstrate rapid BNP release in response to cardiac ischemia, it is unlikely that BNP will be used to diagnose cardiac ischemia, because many other conditions are also associated with modest BNP elevation. In contrast, BNP holds tremendous promise as a prognostic marker in patients with ACS. Studies to date have shown consistently that higher BNP levels are associated with worse clinical outcomes, and that BNP provides unique information to clinical variables, other biomarkers, and left ventricular ejection fraction. Future studies are needed to identify the therapeutic implications of BNP elevation in patients with ACS. Copyright © 2003 by Current Science Inc.

引用

页码：271 / 277

页数：6

共 40 条

[1]

Edwards B.S., Zimmerman R.S., Schwab T.R., Et al., Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor, Circ. Res., 62, pp. 191-195, (1988)

[2]

Yan W., Sheng N., Seto M., Et al., Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart, J. Biol. Chem., 274, pp. 14926-14935, (1999)

[3]

Hooper J.D., Scarman A.L., Clarke B.E., Et al., Localization of the mosaic transmembrane serine protease corin to heart myocytes, Eur. J. Biochem., 267, pp. 6931-6937, (2000)

[4]

Potter L.R., Hunter T., Guanylyl cyclase-linked natriuretic peptide receptors: Structure and regulation, J. Biol. Chem., 276, pp. 6057-6060, (2001)

[5]

Rademaker M.T., Charles C.J., Kosoglou T., Et al., Clearance receptors and endopeptidase: Equal role in natriuretic peptide metabolism in heart failure, Am. J. Physiol., 273, (1997)

[6]

Maisel A.S., Koon J., Krishnaswamy P., Et al., Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction, Am. Heart J., 141, pp. 367-374, (2001)

[7]

Lubien E., DeMaria A., Krishnaswamy P., Et al., Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings, Circulation, 105, pp. 595-601, (2002)

[8]

Yu C.M., Sanderson J.E., Shum I.O., Et al., Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern, Eur. Heart J., 17, pp. 1694-1702, (1996)

[9]

Dao Q., Krishnaswamy P., Kazanegra R., Et al., Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting, J. Am. Coll. Cardiol., 37, pp. 379-385, (2001)

[10]

Davis M., Espiner E., Richards C., Et al., Plasma brain natriuretic peptide in assessment of acute dyspnoea, Lancet, 343, pp. 440-444, (1994)

← 1 2 3 4 →